[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Caja Costarricense de Seguro Social\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,78,103,124,144,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100634382","epidemiology-and-management-of-cutaneous-t-cell-lymphoma-at-hospital-mxico-costa-rica-100634382",false,"NCT07538960","Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.","Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.\n* Patients aged 18 years or older, of both sexes.\n* Patients with at least one dermatological evaluation recorded during the study period.\n* Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and\u002For systemic treatments.\n\nExclusion Criteria:\n\n* Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.\n* Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.\n* Duplicate or inconsistent records that hinder the correct identification and classification of the patient.\n* Patients attended outside the established study period.\n* Patients outside the age range.\n* Patients who do not belong to the Dermatology Service of Hospital México.","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","OBSERVATIONAL","Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.",[24,25,26],"Lymph Node Cancer","Cutaneous","T-cell Lymphoma",[28,29,30,31],"Linfoma","Cutaneous Lymphoma","T-Cell Lymphoma","Therapy","NOT_YET_RECRUITING","2026-04-13",{"date":35,"type":36},"2026-04-20","ACTUAL",{"date":38,"type":20},"2026-05",{"date":40,"type":20},"2027-05",{"name":42,"class":43},"Caja Costarricense de Seguro Social","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":77,"locationsCount":44},"100627417","atopic-dermatitis-treated-with-dupilumab-and-jak-inhibitors-in-costa-rica-100627417","NCT07448363","Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria\n* Moderate-to-severe disease requiring systemic or advanced therapy\n* Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care\n* Evaluated in participating dermatology centers in Costa Rica\n* Available clinical records with baseline and follow-up information\n\nExclusion Criteria:\n\n* Lack of sufficient clinical data for severity or treatment assessment",{"count":53,"type":20},50,"5 Years","The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?\n\nWhat treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?\n\nParticipants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.",[57,58,59,60,61,62],"Atopic Dermatitis","Atopic Dermatitis (AD)","Atopic Dermatitis (Eczema)","Atopic Dermatitis Patients","Atopic Dermatitis \u002F Eczema","Atopic Dermatitis, Unspecified",[64,65,66,67,68,69,70],"Registry","Dupilumab","Abrocitinib","Upadacitinib","JAK-inhibitor","Atopic dermatitis","Baricitinib","2026-04-02",{"date":73,"type":36},"2026-04-08",{"date":38,"type":20},{"date":76,"type":20},"2031-05",{"name":42,"class":43},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":102,"locationsCount":44},"100627415","psoriasis-comorbidities-at-hospital-caldern-guardia-100627415","NCT07448337","Psoriasis Comorbidities at Hospital Calderón Guardia","Prevalence of Metabolic Comorbidities, Atherosclerotic Arterial Disease, and Psoriatic Arthritis in Patients With Psoriasis and Their Association With Clinical Severity and Therapeutic Profile Among Patients Treated at Hospital Rafael Ángel Calderón Guardia During 2024-2025","Inclusion Criteria:\n\n* Patients evaluated in outpatient clinics during the period 2024-2025.\n* Patients receiving systemic therapy and\u002For phototherapy.\n* Patients aged 12 years or older, of any sex.\n* Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis.\n* At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period.\n* Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.\n\nExclusion Criteria:\n\n* Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile.\n* Patients managed exclusively with topical therapies.\n* Duplicate or inconsistent records, preventing accurate patient classification.\n* Cutaneous conditions not compatible with psoriasis.","12 Years",{"count":19,"type":20},"The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics and severity profiles of psoriasis patients?\n\nWhat treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes?\n\nPatients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.",[89,90,91,92],"Psoriasis","Psoriasis Arthritis","Psoriasis (PsO)","Psoriasis Patients",[94,95,89,96,97,98],"Comorbidities","Costa Rica","Real-world data","Disease severity","Epidemiology",{"date":73,"type":36},{"date":38,"type":20},{"date":40,"type":20},{"name":42,"class":43},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":123,"locationsCount":44},"100627668","clinical-epidemiologic-and-therapeutic-characterization-of-pediatric-psoriasis-in-the-costa-rican-social-security-system-100627668","NCT07451626","Clinical, Epidemiologic, and Therapeutic Characterization of Pediatric Psoriasis in the Costa Rican Social Security System","Epidemiological and Therapeutic Characterization Study of Psoriatic Disease in Patients Under 18 Years of Age at the Costa Rican Social Security (2018-2025)","Inclusion Criteria:\n\n* Patients younger than 18 years at the time of psoriasis diagnosis.\n* Clinical diagnosis of psoriasis established by a specialist physician (dermatologist or trained pediatrician) or by a general practitioner within the Costa Rican Social Security System (CCSS).\n* Patients evaluated in CCSS healthcare facilities between January 2018 and December 2025.\n* Clinical records containing sufficient information on key epidemiologic and therapeutic variables relevant to the study (age, sex, date of diagnosis, clinical subtype, and treatment received).\n\nExclusion Criteria:\n\n* Patients aged 18 years or older at the time of psoriasis diagnosis.\n* Clinical records incomplete or lacking sufficient information for analysis of the main study variables.\n* Patients with uncertain or unconfirmed diagnosis of psoriasis.",{"count":111,"type":20},300,"The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica?\n\nWhat disease severity profiles, comorbidities, and treatments are observed in routine care?\n\nAll patients \\\u003C18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.",[114],"Pediatric Psoriasis",[95,98,116,89,117],"Pediatric","Real-Word","2026-04-01",{"date":120,"type":36},"2026-04-07",{"date":38,"type":20},{"date":40,"type":20},{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":131,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":142,"leadSponsor":143,"locationsCount":44},"100627422","generalized-pustular-psoriasis-registry-in-costa-rica-100627422","NCT07448428","Generalized Pustular Psoriasis Registry in Costa Rica","National Registry of Patients With Generalized Pustular Psoriasis Treated Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Confirmed diagnosis of generalized pustular psoriasis (GPP) established by a board-certified dermatologist based on compatible clinical and\u002For histopathologic criteria.\n* Registered diagnosis of GPP in the institutional electronic health record system (EDUS code L401) during the study period.\n* Patients of any age and sex receiving care within participating centers of the Costa Rican Social Security system.\n* Availability of clinical information sufficient for registry data entry and follow-up according to routine care.\n\nExclusion Criteria:\n\n* Patients without a confirmed diagnosis of generalized pustular psoriasis (GPP) or with alternative pustular dermatoses (e.g., acute generalized exanthematous pustulosis) not meeting GPP diagnostic criteria.\n* Absence of verifiable diagnosis in the institutional electronic health record (EDUS) or insufficient documentation to confirm GPP.\n* Patients whose clinical records lack the minimum data required for registry variables or follow-up within routine care.",{"count":53,"type":20},"The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national registry. The main question it aims to answer is:\n\nWhat are the clinical, epidemiological, and therapeutic characteristics of patients with generalized pustular psoriasis registered in the country, and how do these relate to disease severity and evolution?\n\nPatients with GPP receiving routine dermatologic care in participating centers will have their demographic, clinical, severity, comorbidity, and treatment data recorded using a standardized case report form. Clinical assessments (e.g., GPPASI, PASI\u002FBSA, DLQI), laboratory results, triggers, complications, and therapies will be documented and updated during periodic follow-up visits as part of usual care.",[134,135],"Generalized Pustular Psoriasis","Generalized Pustular Psoriasis (GPP)",[89,64,95,137],"Generalized pustular psoriasis","2026-03-06",{"date":140,"type":36},"2026-03-09",{"date":38,"type":20},{"date":76,"type":20},{"name":42,"class":43},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":151,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":159,"locationsCount":44},"100627420","costa-rican-registry-of-il-23-inhibitors-in-psoriatic-disease-100627420","NCT07448402","Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and\u002For psoriatic arthritis based on rheumatologic criteria.\n* Receiving IL-23 inhibitor therapy (guselkumab or risankizumab).\n* Treated within participating Costa Rican public health centers.\n* Availability of sufficient clinical records to complete registry data (history, follow-up, labs).\n* Age ≥12 years, any sex.\n\nExclusion Criteria:\n\n* None specified (all patients meeting inclusion criteria are eligible).",{"count":53,"type":20},"The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and\u002For psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:\n\n* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice?\n* What is the safety profile and treatment persistence of IL-23 inhibitors in this population?\n* Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA\u002FBASDAI) and adverse-event reporting through a national registry.",[89,90,91],[89,155,64,95],"IL-23",{"date":140,"type":36},{"date":38,"type":20},{"date":76,"type":20},{"name":42,"class":43},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":169,"conditions":170,"keywords":177,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":44},"100627419","epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-hansens-disease-in-costa-rica-2018-2025-100627419","NCT07448389","Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Hansen's Disease in Costa Rica (2018-2025)","Retrospective Observational Study for the Epidemiological, Clinical, Diagnostic, and Therapeutic Characterization of Hansen's Disease With Confirmed Diagnosis in Costa Rica During 2018-2025","Inclusion Criteria:\n\n* Confirmed diagnosis of Hansen's disease.\n* Diagnosis between 1 January 2018 and 31 December 2025.\n* Any age or sex.\n* Available digital clinical record.\n* Case reported in national surveillance (VE-01).\n* Diagnosed or treated in Costa Rican public health institutions.\n\nExclusion Criteria:\n\n* Cases whose diagnosis was reviewed and reclassified as another disease.",{"count":168,"type":20},130,"The goal of this observational retrospective study is to characterize the epidemiologic, clinical, diagnostic, and therapeutic features of Hansen's disease cases in Costa Rica between 2018 and 2025. The main questions it aims to answer are:\n\nWhat are the epidemiologic and clinical characteristics of confirmed Hansen's disease cases in Costa Rica?\n\nWhat diagnostic methods, treatments, complications, and outcomes are observed in routine care?\n\nAll confirmed Hansen's disease cases recorded in national surveillance and with available clinical records during 2018-2025 will be included. Data will be obtained from electronic health records and Ministry of Health reports without participant contact.",[171,172,173,174,175,176],"Leprosy","Hansen's Disease","Leprosy--Patients","Lepromatous Leprosy","Leprosy, Multibacillary","Leprosy Neuropathy",[171,95,178,179],"Hansen's disease","Hansen",{"date":140,"type":36},{"date":38,"type":20},{"date":183,"type":20},"2026-12",{"name":42,"class":43},""]